169 related articles for article (PubMed ID: 36972293)
21. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
22. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children.
Wahn U; Bos JD; Goodfield M; Caputo R; Papp K; Manjra A; Dobozy A; Paul C; Molloy S; Hultsch T; Graeber M; Cherill R; de Prost Y;
Pediatrics; 2002 Jul; 110(1 Pt 1):e2. PubMed ID: 12093983
[TBL] [Abstract][Full Text] [Related]
24. Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study.
Papp KA; Gooderham M; Droege M; Merritt C; Osborne DW; Berk DR; Thurston AW; Smith VH; Welgus H
J Drugs Dermatol; 2020 Aug; 19(8):734-740. PubMed ID: 32845114
[TBL] [Abstract][Full Text] [Related]
25. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
26. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
27. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis.
Papp KA; Menter MA; Raman M; Disch D; Schlichting DE; Gaich C; Macias W; Zhang X; Janes JM
Br J Dermatol; 2016 Jun; 174(6):1266-76. PubMed ID: 26800231
[TBL] [Abstract][Full Text] [Related]
28. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
29. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis.
Robbins K; Bissonnette R; Maeda-Chubachi T; Ye L; Peppers J; Gallagher K; Kraus JE
J Am Acad Dermatol; 2019 Mar; 80(3):714-721. PubMed ID: 30612986
[TBL] [Abstract][Full Text] [Related]
30. TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.
Forman SB; Pariser DM; Poulin Y; Vincent MS; Gilbert SA; Kieras EM; Qiu R; Yu D; Papacharalambous J; Tehlirian C; Peeva E
J Invest Dermatol; 2020 Dec; 140(12):2359-2370.e5. PubMed ID: 32311398
[TBL] [Abstract][Full Text] [Related]
31. Indoor salt water baths followed by artificial ultraviolet B light for chronic plaque psoriasis.
Peinemann F; Harari M; Peternel S; Chan T; Chan D; Labeit AM; Gambichler T
Cochrane Database Syst Rev; 2020 May; 5(5):CD011941. PubMed ID: 32368795
[TBL] [Abstract][Full Text] [Related]
32. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
[TBL] [Abstract][Full Text] [Related]
33. Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis.
Bhatia N; Stein Gold L; Kircik LH; Schreiber R
J Drugs Dermatol; 2019 Aug; 18(8):790-796. PubMed ID: 31424709
[TBL] [Abstract][Full Text] [Related]
34. A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).
Papp KA; Barber K; Bissonnette R; Bourcier M; Lynde CW; Poulin Y; Shelton J; Toole J; Vieira A; Poulin-Costello M
J Eur Acad Dermatol Venereol; 2015 Feb; 29(2):361-366. PubMed ID: 24980988
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study.
Liu L; Lou H; Zhou J; Shen Y; Zheng M; Ruan Z
Biomed Res Int; 2019; 2019():9072683. PubMed ID: 31187048
[TBL] [Abstract][Full Text] [Related]
37. Randomized Phase 3 trial demonstrating high efficacy, favourable safety and convenience of a novel calcipotriol and betamethasone dipropionate cream for the treatment of psoriasis.
Pinter A; Reich A; Arenberger P; Gold LS; Armstrong A; Iversen L; Praestegaard M; Augustin M
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2327-2335. PubMed ID: 37432045
[TBL] [Abstract][Full Text] [Related]
38. A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
Thaçi D; Ortonne JP; Chimenti S; Ghislain PD; Arenberger P; Kragballe K; Saurat JH; Khemis A; Sprøgel P; Esslinger HU; Unnebrink K; Kupper H
Br J Dermatol; 2010 Aug; 163(2):402-11. PubMed ID: 20377585
[TBL] [Abstract][Full Text] [Related]
39. Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis.
Jiang C; Du Y; Liu X; Wang J; Ge C; Xu J; Wang S; Li B; Zhu G; Zhang W; Qian Q; Ma C; Zhu X; Zhan Y; Yang Y
Br J Dermatol; 2023 Dec; 190(1):28-36. PubMed ID: 37669307
[TBL] [Abstract][Full Text] [Related]
40. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
